202 related articles for article (PubMed ID: 35379219)
21. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
22. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
23. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
24. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
25. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
26. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitor-related thyroid dysfunction.
Iwama S; Kobayashi T; Yasuda Y; Arima H
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.
Shi Y; Fang J; Zhou C; Liu A; Wang Y; Meng Q; Ding C; Ai B; Gu Y; Yao Y; Sun H; Guo H; Zhang C; Song X; Li J; Xu B; Han Z; Song M; Tang T; Chen P; Lu H; Shui Y; Lou G; Zhang D; Liu J; Liu X; Liu X; Gao X; Zhou Q; Chen M; Zhao J; Zhong W; Xu Y; Wang M
Thorac Cancer; 2022 Feb; 13(3):412-422. PubMed ID: 34935288
[TBL] [Abstract][Full Text] [Related]
31. Clinical biomarkers for thyroid immune-related adverse events in patients with stage III and IV gastrointestinal tumors.
Xing N; Liu J; Hou L; Zhao Y; Ma H; Wang F; Guo Z
Front Immunol; 2024; 15():1381061. PubMed ID: 38774877
[TBL] [Abstract][Full Text] [Related]
32. Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors.
Byrne MM; Lucas M; Pai L; Breeze J; Parsons SK
Eur J Haematol; 2021 Dec; 107(6):650-657. PubMed ID: 34453348
[TBL] [Abstract][Full Text] [Related]
33. Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors.
Haraguchi M; Nakao Y; Narita S; Matsumoto K; Fukushima M; Sasaki R; Honda T; Miuma S; Miyaaki H; Nakao K
Cancer Med; 2023 May; 12(9):10636-10646. PubMed ID: 36934436
[TBL] [Abstract][Full Text] [Related]
34. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland.
Yamauchi I; Hakata T; Sugawa T; Kosugi D; Fujita H; Okamoto K; Ueda Y; Fujii T; Taura D; Harada N; Inagaki N
Endocr J; 2023 Oct; 70(10):987-998. PubMed ID: 37574279
[TBL] [Abstract][Full Text] [Related]
35. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
36. The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.
Ma C; Hodi FS; Giobbie-Hurder A; Wang X; Zhou J; Zhang A; Zhou Y; Mao F; Angell TE; Andrews CP; Hu J; Barroso-Sousa R; Kaiser UB; Tolaney SM; Min L
Cancer Immunol Res; 2019 Jul; 7(7):1214-1220. PubMed ID: 31088848
[TBL] [Abstract][Full Text] [Related]
37. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
38. Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.
von Itzstein MS; Gonugunta AS; Wang Y; Sheffield T; Lu R; Ali S; Fattah FJ; Xie D; Cai J; Xie Y; Gerber DE
Cancer Immunol Immunother; 2022 Sep; 71(9):2169-2181. PubMed ID: 35072744
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
40. Thyroid-related adverse events induced by immune checkpoint inhibitors.
Chera A; Stancu AL; Bucur O
Front Endocrinol (Lausanne); 2022; 13():1010279. PubMed ID: 36204105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
